The OCMX™ is pleased to announce the listing of RepliCel Life Sciences, Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

VANCOUVER, BC, August 27, 2019 /24-7PressRelease/ — RepliCel Life Sciences Inc. is a regenerative medicine company developing multiple products addressing global, large-market opportunities in orthopedics and aesthetics. The company has two strategic, development and commercialization partnerships already in place and is expected to launch its first commercial product within 12 months and have 3 additional products launched commercially by 2023.

RepliCel is developing autologous cell therapies to treat chronic tendon injury, pattern baldness and aging or sun-damaged skin. RepliCel has also developed a proprietary, next-generation dermal injection device (RCI) designed for highly controllable delivery of injectable substances. This device is expected to be market launched in Europe and Hong Kong next year.

In 2017, RepliCel completed three successful phase 1 clinical trials including RCH-01 for pattern baldness from Androgenetic Alopecia (hair loss), RCT-01 for chronic Achilles tendinosis, and RCS-01 for aging and UV-damaged skin. Shiseido Company has an exclusive geographic license for RCH-01 in Asia. Data expected to be released this year from a recently completed a clinical study in Japan, could lead to the product’s near-term market launch in Japan.

In late 2018, RepliCel signed a license and co-development deal for its skin, tendon and injector technologies with YOTOTO (China) Health for Greater China.

The OCMX™ is pleased to announce the listing of RepliCel Life Sciences, Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on RepliCel Life Sciences, Inc. and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that RepliCel Life Sciences, Inc. exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

MANAGEMENT TEAM

Lee Buckler, President, CEO and Director

Mr. Buckler has been an executive in the cell therapy sector since 2000 beginning with Malachite Management in the Stem Cell Technologies group of companies. Before joining the Company he was the Managing Director of Cell Therapy Group, a firm he formed in 2008 where he did business development consulting for companies and organizations in or interested in the cell therapy sector.

Mr. Buckler has a Bachelor’s Degree in Education and a Law Degree. After law school, he did a one year judicial clerkship with the B.C. Supreme Court and was a practicing attorney for three years at Edwards, Kenny & Bray.

Mr. Buckler served six years as the Executive Director of the International Society for Cellular Therapy and just over two years as Director of Business Development for Progenitor Cell Therapy. Mr. Buckler is an advisory board member for RoosterBio Inc.

Dr. Rolf Hoffmann, MD, Chief Medical Officer

Dr. Hoffmann is a European-based practicing dermatologist and clinical researcher who has spent decades researching the fields of pattern hair loss, alopecia areata, endocrinology of the hair follicle and hair follicle morphogenesis. Together with Dr. McElwee, he is the applicant of a landmark patent on the use of hair follicle cup cells and their use in hair diseases. He is the co-discoverer of the Company’s technology and co-founder of RepliCel. He works in his private dermatology clinical practice, as a teaching professor in the Department of Dermatology for Marburg University, and as a researcher on the histopathology of hair diseases on which he has published many articles and text book chapters.

Dr. Hoffmann has participated in dozens of clinical hair studies and consulted for a variety of large companies on hair matters. He is the inventor of TrichoScan®, a computerized technique to measure hair growth, which is part of a privately owned company which markets the device and related services for dermatologists and clinical trial researchers.

Dr. Kevin McElwee, PhD, Chief Scientific Officer

Dr. McElwee, co-discoverer of the Company’s technology and co-founder of RepliCel, is Professor of Biomedical Sciences at the University of Bradford’s School of Chemistry and Biosciences. Previously, he as an Associate Professor in the Department of Dermatology and Skin Health at the University of British Columbia, and Director of the Hair Research Laboratory in the Vancouver Coastal Health Research Institute at Vancouver General Hospital (VGH). His research has been funded by competitive grants awarded by multiple organizations including the Canadian Institutes for Health Research (the equivalent of the National Institutes for Health in the USA).

Dr. McElwee is one of only a small group of research scientists worldwide who studies hair biology and associated diseases. He has worked as a hair research scientist for 12 years and has published over 70 medical journal articles, research abstracts and academic book chapters on hair loss research. Dr. McElwee received his Bachelor of Science degree from the University of Aberdeen, Scotland and his PhD from the University of Dundee, Scotland. Postdoctoral training included three years at the Jackson Laboratory in Maine and four years at the University of Marburg, Germany, studying various hair loss diseases.

Simon Ma, CPA, Chief Financial Officer

Mr. Ma is a Chartered Professional Accountant and has extensive experience with private and public companies. He graduated from the University of British Columbia in 1987 and obtained a degree of Bachelor of Arts in Economics after which he worked in the industry as a Controller until1990 when he started articling. He qualified as a Chartered Accountant in 1994.

Mr. Ma has been a sole public practitioner since 1997 and is practicing under the name of Simon S. Ma Corporation.

He is concurrently serving as chief financial officer of several public companies listed on the TSX Venture Exchange or the Canadian Securities Exchange. He was appointed RepliCel’s Director of Finance of the Company in June 2016 and as the company’s Chief Financial Officer in October 2018.

Dr. Petra Goessens-Rueck, Head of Clinical and Regulatory Affairs

Dr. Goessens-Rueck has been a valuable consultant to RepliCel since its inception assisting with research, development, clinical and regulatory strategy in addition to managing regulatory submissions and most aspects of the Company’s clinical trials. Dr. Goessens-Rueck is a biotech consultant with more than 10 years’ in-depth experience in the development of innovative cellular therapeutics.

She graduated with her Doctorate at the Institute of Pharmacology and Toxicology of Justus-Liebig University of Giessen, Germany in 1996, followed by a post-doctorate research fellowship with INSERM in Paris at their Department of Experimental Medicine. Her work experience includes industry leaders such as Pfizer and Ratiopharm. Since 2012, Dr. Goessens-Rueck has been recognized as one of Europe’s leading consultants for advanced therapies and medicine products (ATMPs).

ABOUT THE OCMX™

The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]


For the original version of this press release, please visit 24-7PressRelease.com here